nach oben

Erschienen in:

31.07.2017 | Original Article

Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer

verfasst von: Hirotsugu Kenmotsu, Yasuhisa Ohde, Kazushige Wakuda, Kazuhisa Nakashima, Shota Omori, Akira Ono, Tateaki Naito, Haruyasu Murakami, Hideaki Kojima, Shoji Takahashi, Mitsuhiro Isaka, Masahiro Endo, Toshiaki Takahashi

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival data for Asian patients treated with adjuvant chemotherapy involving a combination of CDDP and vinorelbine (VNR). This study was performed to evaluate the survival of patients with NSCLC who received postoperative adjuvant chemotherapy comprising CDDP + VNR.

Methods

We retrospectively evaluated patients with NSCLC who received adjuvant chemotherapy comprising CDDP + VNR at the Shizuoka Cancer Center between February 2006 and October 2011.

Results

One hundred patients who underwent surgical resection of NSCLC were included in this study. The patients’ characteristics were as follows: median age 63 years (range 36–74 years), female 34%, never-smokers 20%, and non-squamous NSCLC 73%. Pathological stages IIA, IIB, and IIIA were observed in 31, 22, and 47% of patients, respectively. The 5- and 2-year overall survival rates were 73 and 93%, respectively. The 5- and 2-year relapse-free survival rates were 53 and 62%, respectively. Univariate analysis of prognostic factors showed that patient characteristics (sex, histology, and pathological stage) and CDDP dose intensity were not significantly associated with survival. In 48 patients who developed NSCLC recurrence, the 5-year survival rate after recurrence was 29%, and the median survival time after recurrence was 37 months.

Conclusions

Our results suggest that the prognosis after surgical resection of NSCLC and adjuvant chemotherapy comprising CDDP + VNR might be improving compared with previous survival data of adjuvant chemotherapy for NSCLC.

Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E (2008) A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 3(1):46–52. doi:10.1097/JTO.0b013e31815e8577 CrossRefPubMed

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360. doi:10.1056/NEJMoa031644 CrossRef

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352(25):2589–2597. doi:10.1056/NEJMoa043623 CrossRefPubMed

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9):719–727. doi:10.1016/S1470-2045(06)70804-X CrossRefPubMed

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26(21):3552–3559. doi:10.1200/JCO.2007.13.9030 CrossRefPubMed

Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N (2012) Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan. Respir Investig 50(4):157–161. doi:10.1016/j.resinv.2012.09.002 CrossRefPubMed

Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M, Yokoi K (2011) Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 6(7):1229–1235. doi:10.1097/JTO.0b013e318219aae2 CrossRefPubMed

Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K (2015) Randomized phase II study of adjuvant chemotherapy with long-term S-1 versus cisplatin+ S-1 in completely resected stage II–IIIA non-small cell lung cancer. Clin Cancer Res 21(23):5245–5252. doi:10.1158/1078-0432.CCR-14-3160 CrossRefPubMed

Sonobe M, Okubo K, Teramukai S, Yanagihara K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, Omasa M, Sakai H, Miyahara R, Bando T, Date H (2014) Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer. Cancer Chemother Pharmacol 74(6):1199–1206. doi:10.1007/s00280-014-2595-5 CrossRefPubMed

10.

Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312(25):1604–1608. doi:10.1056/NEJM198506203122504 CrossRefPubMed

11.

Liu J, Dong M, Sun X, Li W, Xing L, Yu J (2016) Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One 11(1):e0146195. doi:10.1371/journal.pone.0146195 CrossRefPubMedPubMedCentral

12.

Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4(4):518–521CrossRefPubMed

13.

Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T (2015) The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Int J Clin Oncol 20(4):668–673. doi:10.1007/s10147-014-0761-8 CrossRefPubMed

14.

Goss GD, O’Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 31(27):3320–3326. doi:10.1200/JCO.2013.51.1816 CrossRefPubMedPubMedCentral

15.

Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crino L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA (2015) Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, Phase III Trial. J Clin Oncol 33(34):4007–4014. doi:10.1200/JCO.2015.61.8918 CrossRef

16.

Wakelee H, Dahlberg S, Keller S, Tester W, Gandara D, Graziano S, Adjei A, Leighl N, Aisner S, Rothman J, Patel J, Sborov M, Mcdermott S, Perez-Soler R, Traynor A, Butts C, Evans T, Horn L, Ramalingam S, Schiller J (2015) Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. J Thorac Oncol 10(suppl 9):796

Titel: Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer
verfasst von: Hirotsugu Kenmotsu
Yasuhisa Ohde
Kazushige Wakuda
Kazuhisa Nakashima
Shota Omori
Akira Ono
Tateaki Naito
Haruyasu Murakami
Hideaki Kojima
Shoji Takahashi
Mitsuhiro Isaka
Masahiro Endo
Toshiaki Takahashi
Publikationsdatum: 31.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3400-z

Springer Medizin

Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer